Dr David Ledingham
Dr Sahana Sathyanarayana
Charlotte Stewart
Robyn Iredale
Victoria Foster
et al. | Alzheimer's Biomarkers and Visuospatial Cognition in Parkinson's Disease: Modification by α-Synuclein and Mediation of Age Effects | 2026 |
|
Dr Jacopo Pasquini
Professor Nicola Pavese
| Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha-Synuclein Seed Amplification Assay | 2026 |
|
Dr Jacopo Pasquini
Professor Nicola Pavese
| Contralateral Spread of Asymmetrical Tremor in Parkinson's Disease | 2026 |
|
Emeritus Professor David Brooks
Professor Nicola Pavese
| Differential Progression of Neuroinflammation in Patients with Isolated Rapid-Eye-Movement Sleep Behavior Disorder | 2026 |
|
Professor Tiago Outeiro
Professor Nicola Pavese
| Neuroimaging and Pathology Biomarkers in Parkinson's Disease and Parkinsonism | 2026 |
|
Emeritus Professor David Brooks
Professor Nicola Pavese
| Positron emission tomography imaging of the cholinergic system in parkinsonian tremor | 2026 |
|
Professor Nicola Pavese
| Spinal cord stimulation therapy for gait impairment in Parkinson’s disease: a double-blinded, randomised feasibility trial with an open extension | 2026 |
|
Professor Nicola Pavese
Dr David Ledingham
| Tremor management strategies in Parkinson’s disease: optimizing patient care | 2026 |
|
Dr Michael Firbank
Emeritus Professor David Brooks
Professor Nicola Pavese
Dr Michael Keogh
| [11C](R)-PK11195 Positron Emission Tomography Imaging of Skull Inflammation in Isolated Rapid-Eye-Movement Sleep Behavior Disorder | 2025 |
|
Professor Nicola Pavese
| A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data | 2025 |
|
Emeritus Professor David Brooks
Professor Nicola Pavese
| A possible role for meningeal inflammation in the early pathogenesis of idiopathic normal pressure hydrocephalus | 2025 |
|
Professor Nicola Pavese
| Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials (npj Parkinson's Disease, (2025), 11, 1, (193), 10.1038/s41531-025-01041-9) | 2025 |
|
Dr Sahana Sathyanarayana
Dr Jacopo Pasquini
Dr David Ledingham
Dr Dipayan Mitra
Dr Naomi Warren
et al. | Case report -Cavernoma involving substantia nigra and nigrostriatal pathway as a rare cause of secondary parkinsonism with a 5 year follow up | 2025 |
|
Professor Nicola Pavese
| Cholinergic patterns correlate with dopamine medication ON freezing of gait in Parkinson's disease | 2025 |
|
Professor Nicola Pavese
| Cognitive and neuropsychiatric profiles distinguish atypical parkinsonian syndromes | 2025 |
|
